[A cooperative phase I-II study of HLBI in patients with malignant tumors].
A cooperative phase I-II study of HLBI (human lymphoblastoid interferon), natural interferon-alpha, was carried out in 38 major institutions in Japan. The eligibility of patients and evaluation of tumor response were based on the 'Criteria for the Evaluation of Clinical Effects of Cancer Chemotherapy on Solid Tumor' by Koyama and Saito, and on Blood Cancer by Kimura. Major objectives of the phase I study were pharmacokinetics and toxicity of HLBI . Based on the toxicity observed in 5 patients with advanced breast cancer, the maximum tolerated dose (MTD) was determined to be 12 X 10(6) unit/day for 1 month. In phase II study, HLBI was administered by i.m. injection at a dose of 3-6 X 10(6) unit/day. Out of 391 patients entered into this study, 280 patients were evaluable. Complete and partial responses were observed in 40 (14.3%) out of 280 evaluable patients, including 11 (19.6%) out of 56 renal cell cancers, 14 (19.2%) out of 73 multiple myelomas, and 9 (17.3%) out of 52 malignant lymphomas among others. Major side effects were fever (69.8%), gastrointestinal disturbances (31.4%), leukopenia (30.7%), thrombocytopenia (27.8%), hepatotoxicities (23.6%) and general fatigue (22.1%).